These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7519201)

  • 1. Urapidil permeates the intact blood-brain barrier.
    Castor G; Schmidt U
    Intensive Care Med; 1994; 20(4):278-81. PubMed ID: 7519201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permeation of the blood-brain barrier by urapidil and its influence on intracranial pressure in man in the presence of compromised intracranial dynamics.
    Anger C; van Aken H; Feldhaus P; Wüsten R; Konig H; Krahling KH; Lawin P
    J Hypertens Suppl; 1988 Dec; 6(2):S63-4. PubMed ID: 3230473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.
    Kolassa N; Beller KD; Sanders KH
    Am J Cardiol; 1989 Aug; 64(7):7D-10D. PubMed ID: 2569265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic profile of urapidil. Consequences for use as an antihypertensive drug].
    van Zwieten PA
    Fortschr Med; 1992 Jun; 110(17):330-2. PubMed ID: 1353745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of hypertensive crises in the perioperative period. Efficacy and safety of the use of urapidil].
    Mastronardi P; Santagata T; Noseda A; Mazzarella B
    Minerva Chir; 1996 Apr; 51(4):227-33. PubMed ID: 8927272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urapidil, a multiple-action alpha-blocking drug.
    Prichard BN; Tomlinson B; Renondin JC
    Am J Cardiol; 1989 Aug; 64(7):11D-15D. PubMed ID: 2569263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental studies on the neurocardiovascular effects of urapidil.
    Gillis RA; Kellar KJ; Quest JA; Namath IJ; Martino-Barrows A; Hill K; Gatti PJ; Dretchen K
    Drugs; 1988; 35 Suppl 6():20-33. PubMed ID: 2900129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.
    Tomlinson B; Renondin JC; Graham BR; Prichard BN
    Eur J Clin Pharmacol; 1991; 41(1):1-3. PubMed ID: 1685992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of urapidil.
    Prichard BN; Renondin JC; Tomlinson B
    J Hypertens Suppl; 1988 Dec; 6(2):S13-9. PubMed ID: 2906695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urapidil. A reappraisal of its use in the management of hypertension.
    Dooley M; Goa KL
    Drugs; 1998 Nov; 56(5):929-55. PubMed ID: 9829161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urapidil, a dual-acting antihypertensive agent: Current usage considerations.
    Buch J
    Adv Ther; 2010 Jul; 27(7):426-43. PubMed ID: 20652659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of serotonin-1A receptor activation and alpha-1 adrenoceptor blockade in the hypotensive effect of 5-methyl-urapidil.
    Mandal AK; Kellar KJ; Gillis RA
    J Pharmacol Exp Ther; 1991 May; 257(2):861-9. PubMed ID: 1674536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of prehospital urapidil for hypertensive emergencies.
    Alijotas-Reig J; Bove-Farre I; de Cabo-Frances F; Angles-Coll R
    Am J Emerg Med; 2001 Mar; 19(2):130-3. PubMed ID: 11239257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid.
    Geracioti TD; Keck PE; Ekhator NN; West SA; Baker DG; Hill KK; Bruce AB; Wortman MD
    Biol Psychiatry; 1998 Aug; 44(3):228-33. PubMed ID: 9693394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of single intravenous administration of urapidil and diltiazem in patients with nonfixed pulmonary hypertension secondary to chronic obstructive lung disease.
    Späh F; Kottman R; Schmidt U
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):517-24. PubMed ID: 7515999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension.
    Rosenthal J; Haerlin R
    Am J Cardiol; 1989 Aug; 64(7):25D-29D. PubMed ID: 2667311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat.
    Ittner KP; Bucher M; Zimmermann M; Grobecker HE; Krämer BK; Taeger K
    Eur J Anaesthesiol; 2002 Jul; 19(7):504-9. PubMed ID: 12113613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive emergencies].
    Hirschl MM; Seilder D; Zeiner A; Wagner A; Heinz G; Sterz F; Laggner AN
    Minerva Cardioangiol; 1994; 42(7-8):365-71. PubMed ID: 7970031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary report on cardiovascular responses to urapidil during intubation and extubation.
    Ye T; Luo A; Ren H; Xu J; Gao M
    Chin Med Sci J; 1993 Dec; 8(4):240-2. PubMed ID: 8032072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension.
    Haenni A; Lithell H
    Metabolism; 1996 Oct; 45(10):1221-9. PubMed ID: 8843176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.